Cristina Gasparetto, MD

home / authors / cristina-gasparetto-md

Articles

$Unmet Needs and Future Perspectives in Newly Diagnosed and Relapsed/Refractory MM$

Unmet Needs and Future Perspectives in Newly Diagnosed and Relapsed/Refractory MM

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

December 15th 2022

The panel shares some unmet needs in the multiple myeloma treatment landscape and exciting developments on the horizon.

Bispecifics in Development for the Treatment of R/R MM

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

December 8th 2022

Dr Tuchman highlights exciting bispecific agents in investigation for the treatment of relapsed/refractory multiple myeloma.

Treatment Options for Patients with Relapsed Multiple Myeloma

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

December 8th 2022

Peter Voorhees, MD, starts a conversation on the best treatment options for patients with multiple myeloma after relapse.

Defining Frail Patients in Multiple Myeloma

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

December 1st 2022

Sascha Tuchman, MD, discusses how frail patients with multiple myeloma are defined in his clinical practice, and what assessment models he utilizes.

Measuring Treatment Response and Duration of Treatment in Transplant-Ineligible MM

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

December 1st 2022

Dr Sascha Tuchman explains how he measures an adequate or successful frontline treatment response in patients with transplant-ineligible NDMM.

Data Updates in Transplant Ineligible NDMM

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

November 25th 2022

Dr Christina Gasparetto compares the results of the MAIA and SWOG0777 trials and discusses how the data has been practice-changing.

Selecting Frontline Treatment Regimens for Transplant-Ineligible MM

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

November 25th 2022

Dr Varga and Dr Tuchman explain the factors for consideration when choosing an initial treatment regimen for patients with transplant-ineligible NDMM.

Patient Profiles: Transplant-Ineligible Newly-Diagnosed Multiple Myeloma

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

November 17th 2022

Drs Tuchman and Gasparetto present two profiles of patients with transplant-ineligible NDMM.

Assessing Response and Duration of Treatment in Transplant-Eligible NDMM

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

November 17th 2022

Cristina Gasparetto, MD, details how to assess treatment response and duration of treatment for transplant-eligible NDMM.

Evaluating MRD-Guided Therapy in Patients with NDMM

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

November 10th 2022

Dr Cindy Varga explains the design and results of the MASTER study presented at ASH [American Society of Hematology Annual Meeting] 2021.

Patient Profile: A 59-Year-Old Man with Transplant Eligible Newly-Diagnosed Multiple Myeloma (NDMM)

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

November 3rd 2022

Cindy Varga, MD, presents a profile of a 59-year-old patient diagnosed with transplant-eligible multiple myeloma.

Available Induction Regimen Options for Patients with Transplant-Eligible NDMM

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

November 3rd 2022

The panel discusses triplet and quadruplet regimen options for transplant-eligible NDMM, and the clinical implications of the DETERMINATION study.

$Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.$

Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma

Paul G. Richardson, MD;Cristina Gasparetto, MD

May 23rd 2022

Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.

PFS With Ixazomib + Pomalidomide and Dexamethasone in RRMM: Upcoming Trial Data

Paul G. Richardson, MD;Cristina Gasparetto, MD

April 18th 2022

Experts share their excitement for upcoming PFS trial data to be presented on the combination of ixazomib, pomalidomide, and dexamethasone in multiple myeloma.

RRMM: Ixazomib Plus Pomalidomide and Dexamethasone

Paul G. Richardson, MD;Cristina Gasparetto, MD

April 11th 2022

Expert perspectives on the triplet combination of ixazomib, pomalidomide, and dexamethasone in multiple myeloma presented at the 2021 ASH [American Society of Hematology] Annual Meeting.

Importance of MRD in Treating Patients With Multiple Myeloma

Paul G. Richardson, MD;Cristina Gasparetto, MD

April 11th 2022

Continuing their discussion on the management of multiple myeloma, experts Paul Richardson, MD, and Cristina Gasparetto, MD, consider the value of minimal residual disease as a marker.

In-Class Transition From Bortezomib to Ixazomib in MM: ASH 2021 Update

Paul G. Richardson, MD;Cristina Gasparetto, MD

April 4th 2022

Insight on the ASH 2021 update highlighting response rates and discontinuation in patients who received in-class transition from bortezomib to ixazomib for multiple myeloma.

IRd in Multiple Myeloma: Patient-Reported Adherence and Outcomes

Paul G. Richardson, MD;Cristina Gasparetto, MD

April 4th 2022

Reflections on the patient-reported adherence and outcome data with IRd (ixazomib, lenalidomide, dexamethasone) therapy after an in-class transition from bortezomib to ixazomib for patients with multiple myeloma.

Proteasome Inhibition in MM: In-Class Transition From Bortezomib to Ixazomib

Paul G. Richardson, MD;Cristina Gasparetto, MD

March 28th 2022

Experts Paul Richardson, MD, and Cristina Gasparetto, MD, discuss trial data analyzing the in-class transition from bortezomib to ixazomib for patients with multiple myeloma.

TOURMALINE-MM1: Ixazomib Therapy in Relapsed/Refractory MM

Paul G. Richardson, MD;Cristina Gasparetto, MD

March 28th 2022

Expert perspectives on data from the TOURMALINE-MM1 trial, which tested ixazomib therapy in patients with relapsed/refractory multiple myeloma.

Multiple Myeloma: Real-World Data With Proteasome Inhibitors

Cristina Gasparetto, MD;Paul G. Richardson, MD

March 21st 2022

Shared insight on how real-world experience and data with proteasome inhibitors in multiple myeloma compare to what was seen in clinical trials.

An Overview of Proteasome Inhibitor Therapy in Multiple Myeloma

Paul G. Richardson, MD;Cristina Gasparetto, MD

March 21st 2022

A broad look at the historical use of proteasome inhibitor therapy in patients with multiple myeloma centered on 3 agents: bortezomib, carfilzomib, and ixazomib.

Optimizing Therapy in Frontline Multiple Myeloma Not Eligible for Transplant

C. Ola Landgren, MD, PhD;Craig Hofmeister, MD, MPH;Cristina Gasparetto, MD;Peter Voorhees, MD

December 24th 2021

Experts in the multiple myeloma field discuss which front-line therapy is best for patients who are treatment ineligible.

Future Directions in Multiple Myeloma Care: Improvements and Unmet Needs

C. Ola Landgren, MD, PhD;Cristina Gasparetto, MD;Craig Hofmeister, MD, MPH;Peter Voorhees, MD

October 21st 2021

After reviewing implications of the MAIA study in multiple myeloma, experts consider unmet needs and future directions in care.

Patient Case #2: A 77-Year-Old Man With Newly Diagnosed MM

C. Ola Landgren, MD, PhD;Cristina Gasparetto, MD;Craig Hofmeister, MD, MPH;Peter Voorhees, MD

October 21st 2021

Panelists discuss the case of a 77-year-old man with newly diagnosed multiple myeloma who wishes to discontinue therapy after achieving a very good partial response.

Patient Case #1: A 75-Year-Old Woman With Newly Diagnosed MM

C. Ola Landgren, MD, PhD;Cristina Gasparetto, MD;Craig Hofmeister, MD, MPH;Peter Voorhees, MD

October 14th 2021

Experts review the case of a 75-year-old woman with newly diagnosed multiple myeloma and discuss treatment selection, continuation, reduction, and duration.

Treatment Options for First-Line Therapy in Transplant-Ineligible MM

C. Ola Landgren, MD, PhD;Cristina Gasparetto, MD;Craig Hofmeister, MD, MPH;Peter Voorhees, MD

October 14th 2021

In-depth considerations for available frontline therapy regimens for patients with transplant-ineligible multiple myeloma.

Transplant-Ineligible MM: Treatment After Adequate Response to Therapy

C. Ola Landgren, MD, PhD;Cristina Gasparetto, MD;Craig Hofmeister, MD, MPH;Peter Voorhees, MD

October 7th 2021

A panel of experts reflects on appropriate actions to take after a patient achieves adequate response to therapy for transplant-ineligible multiple myeloma.